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Essentials
• The effect of alloantibodies on the endothelial expression of thrombomodulin is unknown.
• Thrombomodulin was quantified in stimulated endothelial cells and measured in serum samples.
• Anti-human leukocyte antigen (HLA) I vs. II antibodies have different effects on thrombomodulin.
• Anti-HLA II antibodies may promote a prothrombotic state and contribute to microangiopathy.
Summary. Rationale: Thrombomodulin (TBM) is an anticoagulant and anti-inflammatory transmembrane protein expressed on endothelial cells. Donor-specific alloantibodies, particularly those against human leukocyte antigen (HLA) class II, are associated with microvascular endothelial damage in solid allografts. Objective: Our aim was to characterize the effects of anti-HLA antibodies on endothelial expression of TBM, and in particular, the differential effects of anti-HLA class I compared with those of anti-HLA class II. Methods: We used human glomerular microvascular endothelial cells to examine TBM expression on anti-HLA-treated cells, and we tested sera from transplant recipients for soluble TBM. Results: We found that whereas membrane TBM expression increased in a dose-dependent manner in the presence of anti-HLA class I antibodies, treatment with anti-HLA class II led to minimal TBM expression on the endothelial surface but to a cytosolic accumulation. Platelet adhesion studies confirmed the functional impact of anti-HLA class II. Quantitative densitometry of the membrane lysates further suggested that anti-HLA class II impairs TBM glycosylation. Furthermore, we found a significant association between the presence of circulating anti-HLA class II antibodies in transplant recipients and low serum levels of TBM. Conclusion: These results indicate that ligation of anti-HLA class I and II antibodies produces different effects on the endothelial expression of TBM and on serum levels of TBM in transplant recipients. Anti-HLA class II antibodies may be associated with a prothrombotic state, which could explain the higher occurrence of
Introduction
The most important cause of allograft vasculopathy leading to premature graft loss is chronic antibody-mediated rejection (ABMR) [1, 2] . AMBR is characterized by circulating donor-specific antibodies (DSAs) that interact with the microvascular endothelium, leading to proinflammation, alloreactive T cell activation and thrombotic microangiopathy, morphologically similar to that observed in hemolytic-uremic syndrome (HUS) [1, 3, 4] . Still today, the mechanisms by which these antibodies can produce vascular damage are not well defined. Anti-human leukocyte antigen (HLA) antibodies, the most frequent form of DSA, have a heterogeneous degree of pathogenicity. Clinically, DSAs directed against HLA-II (anti-HLA-II) are more frequently associated with ABMR and portend a poorer prognosis than DSAs against HLA class I (anti-HLA-I) [5] . In renal allografts, anti-HLA-II is more likely to be found in patients with glomerular endothelial lesions, the so-called transplant glomerulopathy [6, 7] . Blocking the complement system with an anti-C5 agent effectively abrogates the chemotaxis of leukocytes and their infiltration into the tissue, but has a limited effect in the long-term prevention of chronic endothelial lesions [8, 9] . These observations indicate the importance of the direct damage caused by anti-HLAs on endothelial cells, which has been poorly studied thus far.
Thrombomodulin (TBM, CD141 or BDCA3 fetomoduline) is a transmembrane glycoprotein expressed by a variety of cells, including endothelial cells [10, 11] . This multidomain protein is present in both membrane and soluble forms. Because of its unique structure, TBM is involved in the regulation of coagulation, complement, inflammation and cell proliferation [11] . At the surface of the endothelium, TBM acts as a receptor for thrombin and blocks the coagulation cascade by modifying thrombin from a procoagulant to an anticoagulant state and activating protein C, which in turn inactivates several prothrombotic factors [12, 13] .
Several indirect observations suggest that TBM may play a role in allograft rejection and in particular in the endothelial damage observed during ABMR. Five per cent of cases of atypical HUS are due to a mutation in TBM [14] . In these patients, mutations in the TBM gene hamper the normal functioning of the protein against the complement system and the coagulation cascade, leading to a microangiopathy similar to transplant glomerulopathy. In xenotransplantation, microvascular thrombosis during acute ABMR is a major barrier to success [15] , and TBM expression reduces the risk of rejection [16] . To date, the effects of anti-HLA antibodies on human TBM are not well defined.
We hypothesized that during the anti-HLA-mediated allograft rejection, the microangiopathic lesions observed could be related to their direct effect on TBM expression on endothelial cells. Therefore, we first examined the effect of anti-HLA-I and II on thrombomodulin expression in human glomerular endothelial cells. Second, we used a cohort of transplant recipients to determine the relationships among serum levels of TBM, allograft rejection and circulating anti-HLAs.
Methods

Microvascular endothelial cell cultures
Primary human glomerular microvascular endothelial cells (GMVECs, Cell Systems, Kirkland, WA, USA) and primary human renal glomerular endothelial cells (ScienCell, San Diego, CA, USA) were used. Briefly, endothelial cells were seeded on coverslips (Bellco Glass Inc., Vineland, NJ, USA) coated with 1% gelatin in flat-bottom 24-well plates (Sarstedt, N€ umbrecht, Germany) in Endothelial Cell Growth Medium MV (PromoCell GmbH, Heidelberg, Germany) supplemented with 5% fetal calf serum (FCS; PromoCell). Three days after plating, the cells were incubated with low-serum medium MV (0.5% FCS) for 4 h and stimulated with IFN-c (PeproTech, Rocky Hill, NJ, USA) at 500 U mL À1 for 48 h to up-regulate the surface expression of HLA-II antigens. Finally, the cells were washed and placed in low-serum medium for 48 h before stimulation with anti-HLA antibodies. Cells with passage numbers 4 and 5 were used in the experiments. We confirmed the stable expression of HLA-II antigens on the endothelial surface following 48 h of rest by flow cytometry (Fig. 1) . Extraction kit according to the manufacturer's protocol (Millipore, Billerica, MA, USA). Extracts were dosed using the BCA Protein Assay kit (Thermo Fisher Scientific). To study the glycosylation, the glycan chondroitinsulfate attached to TBM was removed by digesting the protein extract with chondroitinase ABC (Sigma-Aldrich) for 24 h at 37°C. Protein extracts were subjected to SDS-PAGE and transferred to a nitrocellulose membrane.
The following antibodies were used: mouse monoclonal TBM 1 : 500 (Abcam), mouse monoclonal b-actin 1 : 5000 (Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit polyclonal PECAM 1 : 500 (Abcam), goat anti-mouse 800 1 : 7500, goat anti-mouse 680 1 : 10 000 and goat anti-rabbit 680 1 : 10 000 (Mandel Scientific, Guelph, ON, Canada). Membranes were detected with an Odyssey Imaging System (Li-Cor Biotechnology, Lincoln, NE, USA) and quantified with Image Studio Lite version 5.2 (Li-Cor).
Platelet preparation
Human blood was drawn from healthy donors into ACD tubes (acid citrate dextrose additives; BD Biosciences) and platelets were prepared as described previously [19] .
Platelet adhesion assay
Endothelial cells were grown as above and platelet adhesion was carried out as described previously [20] . Cells were stained with 4',6-diamidino-2-phenylindole and phallo€ ıdin (Alexa Fluor 647; Life Technologies) at a dilution of 1 : 1000 and 1 : 100, respectively, for 20 min at room temperature. Images were acquired with an IX83 fluorescence microscope. Fluorescence was measured with an automatic plate reader (Fluoroskan Ascent; Thermo Fisher Scientific) with an excitation filter of 485 nm and an emission filter of 527 nm in triplicate.
TBM in kidney transplant recipients
Study population and sample collection A total of 55 patients were enrolled in a single-center, observational cohort study with prospective collection of biological samples and clinical data. The participants were recruited between January 2012 and January 2015, during two distinct periods in which consecutive, prospective biobanking and clinical data collection was performed. They were invited to provide a blood sample at the time of a graft biopsy. Serum samples were obtained by centrifugation and stored at À80°C. For the purposes of this analysis, 37 patients were included, based on the presence of the three following histological diagnoses: ABMR, T-cell mediated rejection (TCMR) and non-rejection. Three patients with infections were used as positive controls. Table S1 describes the study population. This protocol was approved by the institutional ethics committee (#2017-3048). All participants gave written informed consent. The activities being reported are consistent with the Principles of the Declaration of Istanbul.
Histological and HLA antibody assessment The biopsies were graded according to the Banff classification of renal allograft pathology by the attending kidney pathologists [21] [22] [23] , blinded to the results of the TBM measurements. Serum samples were screened for anti-HLA antibodies using Flow PRA beads (One Lambda Inc., Canoga Park, CA, USA). Whenever the antibody screening was positive, the samples were tested by Luminex using single antigen beads.
TBM measurements in cell supernatants and serum
Soluble TBM was measured in cell supernatants and patient sera at 1 : 1 and 1 : 50 dilutions, respectively, using the Human Thrombomodulin-BDCA-3 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Groups were compared using the non-parametric MannWhitney test, except for platelet adhesion studies, for which we used the non-parametric Wilcoxon signed rank test because platelets were obtained from different healthy controls for each experiment. To compare TBM levels between groups of patients, multivariable linear regressions were used to adjust for potential confounders. Statistical analyses were performed using SPSS Statistics version 23 (IBM, Armonk, NY, USA). All tests were two tailed, and a P < 0.05 was considered significant.
Results
Endothelial TBM surface expression following anti-HLA stimulation
To study the effect of anti-HLAs on the membrane expression of TBM, we first treated human GMVECs with IFN-c for 48 h to induce expression of HLA-II on the cell surface. We confirmed the presence of both HLA-I and HLA-II on GMVECs following an additional 48 h of incubation under resting conditions (Fig. 1) . The cells were then treated with anti-HLA-I or anti-HLA-II at concentrations that ranged from 0.1 to 2 lg mL À1 , which are expected physiologic concentrations of circulating DSAs in patients [24] .
Upon stimulation with anti-HLA-I, TBM expression increased in a dose-dependent manner up to 1 lg mL À1 ( Fig. 2A and B) ; these results were similar when cells were not pre-treated with IFN-c (Fig. S1 ). By contrast, TBM expression was not significantly increased on GMVECs treated with anti-HLA-II, even at a concentration of 2 lg mL À1 ( Fig. 2A and B) . We observed a similar response when another human glomerular endothelial cell line was used (Fig. S2) . Similar results were also found using a different detection antibody (Fig. S3 ) and another stimulating anti-HLA-II antibody (Fig. S4) . To further confirm the prothrombotic effect of TBM modulation, we measured the surface expression of the EPCR following treatment with anti-HLA antibodies. The results were similar to those obtained for TBM; that is, stimulation with anti-HLA-I increased the expression, whereas anti-HLA-II did not (Fig. S5) . Next, membrane proteins were differentially extracted from GMVECs using non-denaturing conditions [25] , and TBM was measured on the membrane fraction by western blot. Quantitative densitometry confirmed that stimulation with anti-HLA-I produced a large amount of the protein, whereas only a minimal amount was found on the membrane lysates from anti-HLA-II-treated cells (Fig. 2C and  D) . We did not find TBM on the membrane of unstimulated, isotype-stimulated or TNF-a-stimulated cells. Of note, we observed that the molecular weight of the protein isolated from anti-HLA-II-stimulated cells was 4-5 K higher than with anti-HLA-I stimulation. We also noted a second large band near 160 K in the well of the anti-HLA-I-treated cells. This band has been identified in the past as chondroitin sulfate bound to the TBM [26] , and it has been suggested that this sulfate group enhances the antithrombin-dependent anticoagulant function of TBM [27, 28] . To confirm this hypothesis, we digested the extracts with chondroitinase and repeated the western blot. We observed that the 160 KDa band disappeared (Fig. S6 ). In addition, we noted two new bands at approximately 120 KDa, which corresponds to the weight obtained previously by others in different cell lines (human umbilical vein endothelial cells, human pulmonary artery cells and human aortic endothelial cells), which could be due to residual attachment of acidic phospholipids [29, 30] . Taken together, these data indicate that stimulation with anti-HLA-I increased membrane TBM, whereas anti-HLA-II treatment had only a minimal effect. They further suggest that this differential effect may be a result of an impairment of TBM glycosylation protein following anti-HLA-II stimulation.
Functional studies of platelet adhesion
We next sought to determine the functional impact of anti-HLA antibodies on platelet adhesion. We used normal platelets from healthy volunteers. Adherence under static conditions was examined by labeling the platelets with calcein-AM and measuring the binding by immunofluorescence. We observed that platelet adhesion was increased on endothelial cells stimulated by anti-HLA-II (Fig. 3A-B) . To quantify these data, we measured the fluorescence of adherent platelets for each condition (Fig. 3C ). We observed a significant increase in platelet adherence with anti-HLA-II treatment compared with non-stimulated cells (mean fluorescence intensity, 0.52 AE 0.07 vs. 0.40 AE 0.09 arbitrary units; P = 0.03).
Overall, these results suggest that anti-HLA-II antibodies lead to increased platelet adherence on glomerular endothelial cells, which could explain the higher incidence of thrombotic microangiopathy in patients with these alloantibodies.
Endothelial TBM release following anti-HLA stimulation
To determine whether the difference in TBM expression on the endothelial surface observed between anti-HLA-I and II treatments was because of a release of TBM from the cells following stimulation, we measured soluble TBM in the culture supernatants. As displayed in Fig. 4 , treatment with a low concentration of anti-HLA-I led to a non-significant increase in soluble TBM, whereas stimulations at higher concentrations produced levels similar to non-stimulated cells. Stimulation with anti-HLA-II at any concentration had no effect on soluble TBM levels. Treatment with TNF-a induced a significant release of TBM (65.7 AE 6.5 vs. 43.0 AE 3.4 pg mL À1 ; P = 0.017). Overall, these observations suggest that stimulation of glomerular endothelial cells with either anti-HLA-I or anti-HLA-II had little effect on TBM secretion. Furthermore, the difference observed in supernatants collected after stimulation with anti-HLA-II and TNF-a indicates that the absence of TBM on the endothelial cell surface with both stimulations (Fig. 4) occurs through different mechanisms.
Endothelial intracellular TBM expression following anti-HLA stimulation
Because we detected neither membrane nor soluble TBM in response to stimulation with anti-HLA-II, we sought to explore whether TBM could be detected intracellularly. GMVECs were stimulated as above and permeabilized prior to staining for TBM. Intracellular TBM expression in GMVECs increased following stimulation with anti-HLA-II at a concentration up to 1.0 lg mL À1 ( Fig. 5A and B). The photomicrograph in Fig. 5C and D) . We found negligible TBM with IgG isotype and TNF-a. Staining for PECAM1 confirmed that there was no contamination between cytosolic and membrane fractions during the extraction (Fig. 5C) . Finally, to examine whether the TBM was degraded or secreted, we repeated the experiment under the same conditions as above, but kept the cells in culture and measured TBM in the supernatant following a prolonged period of rest. We noted an increase in TBM levels after 36 and 48 h of rest compared with 12 h in the cells treated with anti-HLA-II (Fig. S7) . Taken together, these results indicate that anti-HLA-II stimulation increases TBM that remains sequestered intracellularly and is ultimately secreted.
Serum TBM in kidney transplant recipients
To further study the clinical relevance of these in vitro findings, we measured serum TBM levels in 37 kidney allograft recipients who underwent serum collection and had circulating DSAs detected concurrently with a graft biopsy. Specifically, sera from 12 patients with histologic diagnoses of ABMR were compared with those from 12 patients with TCMR and 10 non-rejectors. Three additional patients with concurrent infection at the time of blood collection were used as controls. Patients with ABMR and TCMR and non-rejectors were further classified according to the presence of circulating HLA-I and HLA-II antibodies. Patient baseline characteristics and DSA status are displayed in Table S1 . The subjects were mostly middle-aged first transplant recipients undergoing a triple immunosuppression maintenance regimen.
We first compared TBM levels among the ABMR, TCMR and non-rejector groups (Fig. 6A) . TBM levels of 3100 AE 1300 pg mL À1 have been reported in healthy volunteers and a range of 3000-300 000 pg mL À1 TBM has been observed in patients with myocardial infarction [11, 31, 32] . Levels in the present cohort ranged between 7243 and 22 805 pg mL À1 . Patients with ABMR had levels similar to those of non-rejectors but lower than those observed in patients with TCMR (10 708 AE 1414 vs. 12 801 AE 806 pg mL
À1
; P = 0.036). Multivariable linear regression analyses adjusted for the potential confounders identified by a P-value below or equal to 0.20 in Table S1 (gender, time post-transplant, prednisone dose and mycophenolate) confirmed that there was no difference between non-rejectors and ABMR (P = 0.28), but significantly lower levels in ABMR compared with TCMR (b = À4642 AE 1971 pg mL À1 ; P = 0.033). We next compared TBM levels according to the DSA status. As shown in Fig. 6(B) , the levels were lower in patients with anti-HLA-II compared with those in both patients with no DSA (8894 AE 649 vs. 12 483 AE 698 pg mL À1 ; P = 0.033) or those with anti-HLA-I (8894 AE 649 vs. 12 875 AE 747 pg mL
; P = 0.018). Only one patient had both anti-HLA-I and II detected in his serum. His TBM level was similar to that of patients with anti-HLA-II only. Taken together, these data suggest that circulating anti-HLA-II DSAs are associated with lower serum levels of TBM when compared with TBM levels in patients without DSA or in patients with circulating anti-HLA-I.
To reconcile these findings with the observation that TBM levels were similar in culture supernatants following anti-HLA-I and II stimulations, we tested the hypothesis that persistent stimulation leads to an accumulation of TBM by treating the endothelial cells for a prolonged time-course. We observed a clear trend towards higher levels following treatment for 48 and 72 h (Fig. S8) .
Discussion
In this report, we demonstrate that anti-HLA-I and anti-HLA-II have direct and different effects on TBM expression in human glomerular endothelial cells. Specifically, we observed that treatment with anti-HLA-II led to intracellular TBM accumulation with little expression on the cell surface and no extracellular accumulation. On the other hand, anti-HLA-I treatment produced a large and dose-dependent increase in the expression of membrane TBM. Our results suggest that anti-HLA-I can promote TBM expression, which can somewhat counteract the damaging effects of these antibodies on endothelial cells. By contrast, ligation of anti-HLA-II on the glomerular endothelium seems to promote the hemostatic balance toward pro-thrombosis, which may explain the predominance of microangiopathic lesions observed with this class of antibodies. These findings are novel because they characterize the direct effect of anti-HLA-I compared with anti-HLA-II on TBM, a component of the vascular endothelium that has not been well studied so far. Because anti-HLA-II appeared to have no effect on the membrane TBM, we tested the hypothesis that it prevented the transport of TBM to the cell surface. Indeed we observed that in anti-HLA-II-treated cells, TBM was confined intracellularly, suggesting an effect different from what was observed with anti-HLA-I. Furthermore, we demonstrated that soluble TBM levels are low in kidney recipients with circulating DSAs, which adds clinical relevance to the in vitro data. In patients, we found lower levels of serum TBM in the presence of circulating anti-HLA-II. Although TBM levels have been used as a marker of injury [33] , it has been postulated that endothelial injury produces a focal loss of TBM, resulting in a local prothrombotic tendency [34] . Several potential therapeutic applications of recombinant TBM are currently being tested, notably for sepsis and coagulopathy [35] . Recent reports have described the use of recombinant TBM to prevent thrombotic microangiopathy or veno-occlusive disease following bone marrow and liver transplantation [36] [37] [38] [39] .
The various effects of anti-HLA-I on the endothelium and the pathways involved are beginning to be unveiled [40, 41] . The interaction between antigens and anti-HLA-I causes the phosphorylation and activation of several kinases and G proteins, including Rho, Src kinase and focal adhesion kinase. Activation of Rho has been shown to lead to neointima formation and transplant vasculopathy [42] . Anti-HLA-I also triggers the production of vascular endothelial growth factor (VEGF), which acts in an autocrine fashion to activate endothelial cells [43] . Because it has been reported that VEGF induces TBM expression in a concentration-dependent manner on the endothelial cell surface, the effect observed here could be mediated by VEGF [44] . Of note, the effect observed with TNF-a is because of a shutdown of TBM synthesis by a transcriptional mechanism involving NF-jB, which does not seem to be at play for anti-HLAs [17] .
The interaction between anti-HLA-II and endothelial cells has been less well characterized. Thus far, the signaling of HLA-II has been mostly examined in antigen-presenting cells rather than in endothelial cells [45] . The HLA-II molecules have a short cytoplasmic tail without known signaling motifs, so that in B cells, signal transduction occurs following association with the Ig-a/Ig-b (CD79a/CD79b) heterodimer, leading to activation of the protein tyrosine kinase Syk [46] . Recently, Lion et al. reported that, similar to anti-HLA-I, stimulation of endothelial cells with anti-HLA-II leads to the phosphorylation of Akt, ERK and MEK [47] . It is tempting to speculate that activation of the ERK pathway is responsible for the increase in TBM observed within the glomerular endothelial cells.
It has been shown that internalization of TBM by endocytosis, directed by the lectin-like domain of the molecule, can regulate its surface expression [48, 49] . Thus we speculated that the accumulation of TBM observed intracellularly, without expression on the cell surface, could be because of an effect of anti-HLA-II on this process. Early studies on TBM reported that homocysteine increases TBM mRNA and synthesis but disrupts its transit to the cell surface by an undefined mechanism [26] . Here, we observed that the protein produced following anti-HLA-II stimulation has a different molecular weight from the one produced with anti-HLA-I treatment, a 160 KD protein, previously identified as TBM glycosylated with chondroitin sulfate [26] . We further observed that digestion with chondroitinase abrogates this band, supporting the hypothesis that anti-HLA-II may have an effect on the glycosylation of TBM. We may speculate that an alteration in either this glycosylation, or the TBM proteoglycan itself, is related to the lack of transport to the membrane.
This work has some limitations. The evidence presented here is based on in vitro data. However, we used patient samples from a well-defined prospective cohort and found a significant association between anti-HLA-II and TBM, which supports our experimental findings. Moreover, the experiments were robust across different cell lines, anti-HLA-II stimulation antibodies, TBM detection antibodies and experimental approaches. It would be difficult to use an animal model to test the hypotheses herein, in particular to compare the effect of anti-HLA-I with that of anti-HLA-II. There is currently no adequate in vivo model of MHC class II mismatch in transplantation to specifically study the effect of DSAs against this class in vivo.
In conclusion, these data suggest that anti-HLA-I and II have different effects on the surface expression of TBM in human glomerular endothelial cells, which could explain why the microangiopathic lesions seen in transplant glomerulopathy are predominantly observed in patients with anti-HLA-II. This study provides a rationale for further investigating the pathways involved in TBM expression following stimulation with anti-HLAs and testing TBM as a potential non-immunologic therapeutic target to prevent allograft rejection. 
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